Old Web
English
Sign In
Acemap
>
Paper
>
LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
2020
Corinne Faivre-Finn
David Vicente
Takayasu Kurata
D. Planchard
Luis Paz-Ares
Johan Vansteenkiste
David R. Spigel
Marina Chiara Garassino
M. Reck
Suresh Senan
Jarushka Naidoo
Andreas Rimner
Y.L. Wu
Jhanelle E. Gray
Mustafa Ozguroglu
K H Lee
M. Newton
Luhua Wang
P Thiyagarajah
S. J. Antonia
Keywords:
Durvalumab
Stage III NSCLC
Oncology
Chemoradiotherapy
Medicine
Internal medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
20
Citations
NaN
KQI
[]